Phase I/II study of galiximab, an anti-CD80 antibody, for relapsed or refractory follicular lymphoma

Myron S. Czuczman, Aron Thall, Thomas E. Witzig, Julie M. Vose, Anas Younes, Christos Emmanouilides, Thomas P. Miller, Joseph O. Moore, John P. Leonard, Leo I. Gordon, John Sweetenham, Baha Alkuzweny, Deborah M. Finucane, Bryan R. Leigh

Research output: Contribution to journal › Article › peer-review